TherapeuticsMD (TXMD) Competitors $1.11 +0.02 (+1.83%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TXMD vs. IMRX, STTK, ALTS, IOBT, ALVR, ITRM, CELU, CASI, VTVT, and OMGAShould you be buying TherapeuticsMD stock or one of its competitors? The main competitors of TherapeuticsMD include Immuneering (IMRX), Shattuck Labs (STTK), Janone (ALTS), IO Biotech (IOBT), AlloVir (ALVR), Iterum Therapeutics (ITRM), Celularity (CELU), CASI Pharmaceuticals (CASI), vTv Therapeutics (VTVT), and Omega Therapeutics (OMGA). These companies are all part of the "pharmaceutical products" industry. TherapeuticsMD vs. Immuneering Shattuck Labs Janone IO Biotech AlloVir Iterum Therapeutics Celularity CASI Pharmaceuticals vTv Therapeutics Omega Therapeutics Immuneering (NASDAQ:IMRX) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends. Does the media favor IMRX or TXMD? In the previous week, Immuneering had 4 more articles in the media than TherapeuticsMD. MarketBeat recorded 5 mentions for Immuneering and 1 mentions for TherapeuticsMD. Immuneering's average media sentiment score of 0.12 beat TherapeuticsMD's score of 0.00 indicating that Immuneering is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TherapeuticsMD 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is IMRX or TXMD more profitable? Immuneering has a net margin of 0.00% compared to TherapeuticsMD's net margin of -207.77%. TherapeuticsMD's return on equity of -14.08% beat Immuneering's return on equity.Company Net Margins Return on Equity Return on Assets ImmuneeringN/A -79.19% -69.08% TherapeuticsMD -207.77%-14.08%-9.61% Which has preferable valuation and earnings, IMRX or TXMD? TherapeuticsMD has higher revenue and earnings than Immuneering. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmuneering$320K194.06-$53.47M-$1.97-1.02TherapeuticsMD$1.60M8.02-$10.28MN/AN/A Does the MarketBeat Community favor IMRX or TXMD? TherapeuticsMD received 357 more outperform votes than Immuneering when rated by MarketBeat users. However, 64.44% of users gave Immuneering an outperform vote while only 58.93% of users gave TherapeuticsMD an outperform vote. CompanyUnderperformOutperformImmuneeringOutperform Votes2964.44% Underperform Votes1635.56% TherapeuticsMDOutperform Votes38658.93% Underperform Votes26941.07% Do analysts rate IMRX or TXMD? Immuneering currently has a consensus price target of $12.80, indicating a potential upside of 540.00%. Given Immuneering's stronger consensus rating and higher possible upside, analysts plainly believe Immuneering is more favorable than TherapeuticsMD.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuneering 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38TherapeuticsMD 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, IMRX or TXMD? Immuneering has a beta of -0.33, indicating that its share price is 133% less volatile than the S&P 500. Comparatively, TherapeuticsMD has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Do insiders & institutionals have more ownership in IMRX or TXMD? 67.7% of Immuneering shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 25.0% of Immuneering shares are owned by company insiders. Comparatively, 2.3% of TherapeuticsMD shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryImmuneering beats TherapeuticsMD on 10 of the 16 factors compared between the two stocks. Ad Crypto 101 MediaThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… Get TherapeuticsMD News Delivered to You Automatically Sign up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TXMD vs. The Competition Export to ExcelMetricTherapeuticsMDPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.80M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5990.1317.20Price / Sales8.02196.061,117.09117.04Price / CashN/A57.1643.1037.85Price / Book0.405.094.784.78Net Income-$10.28M$151.83M$120.31M$225.60M7 Day Performance-9.02%-2.14%-1.92%-1.23%1 Month Performance-18.98%-4.56%13.65%0.46%1 Year Performance-51.95%8.87%28.34%15.24% TherapeuticsMD Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TXMDTherapeuticsMD0.4365 of 5 stars$1.11+1.8%N/A-53.8%$12.80M$1.60M0.00420Analyst ForecastGap UpHigh Trading VolumeIMRXImmuneering3.4154 of 5 stars$1.72+5.2%$12.80+644.2%-71.3%$53.41M$320,000.00-0.8360News CoverageGap DownSTTKShattuck Labs2.6671 of 5 stars$1.11-2.6%$8.67+680.8%-82.2%$52.99M$1.66M-0.75100ALTSJanoneN/A$3.75-4.3%N/AN/A$52.76M$7.11M0.00170Gap UpIOBTIO Biotech3.2806 of 5 stars$0.80-1.3%$9.33+1,067.4%-47.2%$52.67MN/A-0.5930News CoveragePositive NewsALVRAlloVir0.7092 of 5 stars$0.46+1.1%N/A-82.7%$52.58MN/A-0.51110News CoverageITRMIterum Therapeutics2.0436 of 5 stars$1.89+4.7%$5.00+165.3%+9.3%$51.87MN/A-0.9410CELUCelularityN/A$2.29+3.2%N/A+28.7%$50.35M$48.20M0.00220CASICASI Pharmaceuticals3.083 of 5 stars$3.18+2.3%$6.00+88.7%-60.4%$49.17M$22.06M-1.39180Positive NewsVTVTvTv Therapeutics2.0038 of 5 stars$15.30+1.8%$35.00+128.8%+69.8%$48.81M$2.02M-3.329Gap UpOMGAOmega Therapeutics2.0244 of 5 stars$0.88-9.3%$9.20+946.6%-65.1%$48.67M$3.09M0.00120 Related Companies and Tools Related Companies Immuneering Alternatives Shattuck Labs Alternatives Janone Alternatives IO Biotech Alternatives AlloVir Alternatives Iterum Therapeutics Alternatives Celularity Alternatives CASI Pharmaceuticals Alternatives vTv Therapeutics Alternatives Omega Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TXMD) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TherapeuticsMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TherapeuticsMD With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
